DK2753928T3 - COMPOSITIONS AND METHODS FOR AUTO ANTIBODY DETECTION - Google Patents
COMPOSITIONS AND METHODS FOR AUTO ANTIBODY DETECTION Download PDFInfo
- Publication number
- DK2753928T3 DK2753928T3 DK11872018.4T DK11872018T DK2753928T3 DK 2753928 T3 DK2753928 T3 DK 2753928T3 DK 11872018 T DK11872018 T DK 11872018T DK 2753928 T3 DK2753928 T3 DK 2753928T3
- Authority
- DK
- Denmark
- Prior art keywords
- sample
- tbi
- cells
- tsh
- thyroid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 77
- 239000000203 mixture Substances 0.000 title claims description 22
- 238000001514 detection method Methods 0.000 title claims description 21
- 210000004027 cell Anatomy 0.000 claims description 190
- 239000000523 sample Substances 0.000 claims description 156
- 102000003911 Thyrotropin Receptors Human genes 0.000 claims description 85
- 108090000253 Thyrotropin Receptors Proteins 0.000 claims description 85
- 102000011923 Thyrotropin Human genes 0.000 claims description 77
- 108010061174 Thyrotropin Proteins 0.000 claims description 77
- 210000001685 thyroid gland Anatomy 0.000 claims description 56
- 230000000903 blocking effect Effects 0.000 claims description 55
- 108060003951 Immunoglobulin Proteins 0.000 claims description 53
- 102000018358 immunoglobulin Human genes 0.000 claims description 53
- 230000004936 stimulating effect Effects 0.000 claims description 46
- 230000009261 transgenic effect Effects 0.000 claims description 44
- 230000027455 binding Effects 0.000 claims description 42
- 238000012360 testing method Methods 0.000 claims description 40
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 38
- 150000007523 nucleic acids Chemical group 0.000 claims description 32
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 28
- 239000005495 thyroid hormone Substances 0.000 claims description 28
- 229940036555 thyroid hormone Drugs 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 239000013068 control sample Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 13
- 230000029918 bioluminescence Effects 0.000 claims description 10
- 238000005415 bioluminescence Methods 0.000 claims description 10
- 210000000170 cell membrane Anatomy 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 9
- 108010052090 Renilla Luciferases Proteins 0.000 claims description 8
- 239000013641 positive control Substances 0.000 claims description 8
- 108700019146 Transgenes Proteins 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 5
- 241000699802 Cricetulus griseus Species 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 150000001413 amino acids Chemical group 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 101150098159 TSHR gene Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 description 72
- 210000002966 serum Anatomy 0.000 description 28
- 201000010099 disease Diseases 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 230000035945 sensitivity Effects 0.000 description 25
- 108060001084 Luciferase Proteins 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 17
- 239000005089 Luciferase Substances 0.000 description 15
- 108700008625 Reporter Genes Proteins 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 12
- 231100000673 dose–response relationship Toxicity 0.000 description 12
- 230000009977 dual effect Effects 0.000 description 11
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 10
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 10
- 229940095074 cyclic amp Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 239000011535 reaction buffer Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 102000009151 Luteinizing Hormone Human genes 0.000 description 9
- 108010073521 Luteinizing Hormone Proteins 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 9
- 239000005556 hormone Substances 0.000 description 9
- 229940040129 luteinizing hormone Drugs 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 8
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 7
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229940028334 follicle stimulating hormone Drugs 0.000 description 7
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 208000003532 hypothyroidism Diseases 0.000 description 6
- 230000002989 hypothyroidism Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002961 luciferase induction Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000015486 thyroid-stimulating hormone receptor activity proteins Human genes 0.000 description 5
- 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108090000363 Bacterial Luciferases Proteins 0.000 description 4
- 108090000331 Firefly luciferases Proteins 0.000 description 4
- 208000015023 Graves' disease Diseases 0.000 description 4
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 4
- 206010028665 Myxoedema Diseases 0.000 description 4
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 4
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 108700010039 chimeric receptor Proteins 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 208000003786 myxedema Diseases 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- -1 ELISA Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 241000736355 Euthyroides Species 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 102000051345 human TSHR Human genes 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 2
- 108010000239 Aequorin Proteins 0.000 description 2
- 241000607620 Aliivibrio fischeri Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 241000254158 Lampyridae Species 0.000 description 2
- 241000254064 Photinus pyralis Species 0.000 description 2
- 241000242743 Renilla reniformis Species 0.000 description 2
- 241000242583 Scyphozoa Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960000874 thyrotropin Drugs 0.000 description 2
- 230000001748 thyrotropin Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 1
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 241000205062 Halobacterium Species 0.000 description 1
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 1
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 description 1
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 description 1
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 1
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 101100154692 Rattus norvegicus Tshr gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001468001 Salmonella virus SP6 Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 102000050868 human CCND2 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/046—Thyroid disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/228,705 US8986937B2 (en) | 2011-09-09 | 2011-09-09 | Compositions and methods for detecting autoantibodies |
| PCT/US2011/050976 WO2013036239A1 (en) | 2011-09-09 | 2011-09-09 | Compositions and methods for detecting autoantibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2753928T3 true DK2753928T3 (en) | 2018-05-22 |
Family
ID=47830166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11872018.4T DK2753928T3 (en) | 2011-09-09 | 2011-09-09 | COMPOSITIONS AND METHODS FOR AUTO ANTIBODY DETECTION |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US8986937B2 (enExample) |
| EP (1) | EP2753928B1 (enExample) |
| JP (1) | JP5908590B2 (enExample) |
| KR (1) | KR101872060B1 (enExample) |
| CN (1) | CN103975239B (enExample) |
| DK (1) | DK2753928T3 (enExample) |
| IN (1) | IN2014KN00742A (enExample) |
| PL (1) | PL2753928T3 (enExample) |
| WO (1) | WO2013036239A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020050208A1 (ja) * | 2018-09-05 | 2020-03-12 | ヤマサ醤油株式会社 | Ｔｓｈ受容体に対する自己抗体活性の迅速測定方法及びキット |
| KR20220002883A (ko) * | 2019-03-12 | 2022-01-07 | 퀴델 코포레이션 | 자가항체 검출용 조성물, 키트, 및 방법 |
| JP7212955B2 (ja) * | 2020-12-28 | 2023-01-26 | ヤマサ醤油株式会社 | 甲状腺刺激ホルモン受容体阻害性自己抗体の活性測定法およびキット |
| CN113686841B (zh) * | 2021-09-01 | 2023-06-30 | 北京利德曼生化股份有限公司 | 定量检测甲状腺素结合力试剂盒及其制备方法、检测方法 |
| WO2023214183A2 (en) | 2022-05-06 | 2023-11-09 | Antibody Analytics Limited | Chemically induced proximity systems |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4537573B2 (ja) | 1997-09-19 | 2010-09-01 | プロメガ・コーポレイシヨン | 熱安定ルシフェラーゼと生産方法 |
| US6747139B1 (en) * | 1997-11-05 | 2004-06-08 | Quest Diagnostics Investments, Inc. | Nucleic acid encoding human thyrotropin receptor |
| US8293879B2 (en) | 2000-03-30 | 2012-10-23 | Diagnostic Hybrids, Inc. | Methods of using chimeric receptors to identify autoimmune disease |
| US8563257B2 (en) * | 2000-03-30 | 2013-10-22 | Diagnostic Hybrids, Inc. | Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity |
| GB0516527D0 (en) * | 2005-08-11 | 2005-09-21 | Arpi Matossian Rogers | Peptides |
| US20080305098A1 (en) | 2005-11-21 | 2008-12-11 | Dr. Fenning Biomed Gmbh | Recombinant Polypeptides and Methods for Detecting and/or Quantifying Autoantibodies Against Tsh Receptor |
| EP2121758B1 (en) * | 2007-02-15 | 2014-08-06 | R S R Limited | Human monoclonal antibodies to the thyrotropin receptor which act as antagonists |
| TW200918058A (en) * | 2007-08-31 | 2009-05-01 | Organon Nv | TSH receptor antagonizing tetrahydroquinoline compounds |
| US7799532B2 (en) * | 2008-11-12 | 2010-09-21 | Hemopet | Detection and measurement of thyroid hormone autoantibodies |
| EP2617735A3 (en) * | 2008-12-24 | 2013-10-16 | Rsr Limited | Human anti tshr antibodies |
-
2011
- 2011-09-09 JP JP2014529656A patent/JP5908590B2/ja active Active
- 2011-09-09 PL PL11872018T patent/PL2753928T3/pl unknown
- 2011-09-09 EP EP11872018.4A patent/EP2753928B1/en active Active
- 2011-09-09 IN IN742KON2014 patent/IN2014KN00742A/en unknown
- 2011-09-09 WO PCT/US2011/050976 patent/WO2013036239A1/en not_active Ceased
- 2011-09-09 US US13/228,705 patent/US8986937B2/en active Active
- 2011-09-09 CN CN201180074180.2A patent/CN103975239B/zh active Active
- 2011-09-09 DK DK11872018.4T patent/DK2753928T3/en active
- 2011-09-09 KR KR1020147009182A patent/KR101872060B1/ko active Active
-
2015
- 2015-02-18 US US14/625,086 patent/US20150233914A1/en not_active Abandoned
-
2020
- 2020-05-11 US US16/871,554 patent/US12174185B2/en active Active
-
2023
- 2023-12-06 US US18/530,800 patent/US20240133882A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013036239A1 (en) | 2013-03-14 |
| JP2014529993A (ja) | 2014-11-17 |
| EP2753928A1 (en) | 2014-07-16 |
| US20150233914A1 (en) | 2015-08-20 |
| PL2753928T3 (pl) | 2018-07-31 |
| JP5908590B2 (ja) | 2016-04-26 |
| EP2753928B1 (en) | 2018-02-07 |
| US20240133882A1 (en) | 2024-04-25 |
| KR20140084022A (ko) | 2014-07-04 |
| US20130065252A1 (en) | 2013-03-14 |
| CN103975239B (zh) | 2016-08-24 |
| US20200340991A1 (en) | 2020-10-29 |
| CN103975239A (zh) | 2014-08-06 |
| KR101872060B1 (ko) | 2018-06-27 |
| IN2014KN00742A (enExample) | 2015-10-02 |
| US12174185B2 (en) | 2024-12-24 |
| US8986937B2 (en) | 2015-03-24 |
| EP2753928A4 (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240133882A1 (en) | Compositions and methods for detecting autoantibodies | |
| JP3442784B2 (ja) | キナーゼ受容体活性化検定法 | |
| US10564159B2 (en) | Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity | |
| JP6654580B2 (ja) | Ｔｓｈ受容体に対する自己抗体の検出 | |
| US10041943B2 (en) | Methods of using chimeric receptors to identify autoimmune disease | |
| CN101076730A (zh) | 通过筛选人或动物组织、血液或体液中的海帕西啶来诊断疾病的方法,以及该方法的治疗性用途 | |
| JP2013231736A (ja) | Ｔｓｈ受容体及び新規ｔｓｈ受容体キメラに対する自己免疫抗体検出方法 | |
| KR101560849B1 (ko) | 자가면역 질환을 확인하기 위해 키메라 수용체를 사용하는 민감하고 신속한 방법 | |
| CN114874993A (zh) | 一种调控猪卵巢颗粒细胞mmp2基因表达的方法 | |
| CN117778551A (zh) | Foxo3作为灵长类动物骨骼肌衰老生物标志物的应用 | |
| Ruediger et al. | Mutagenesis and Expression of the Scaffolding A and A Subunits of PP2A |